Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein

Cell Cycle

Volumn 4, Issue 11, 2005, Pages 1591-1596

  Den Besten, Willem ^a   Kuo, Mei Ling ^a   Williams, Richard T ^a   Sherr, Charles J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; NUCLEOPHOSMIN; PROTEIN MDM2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL AGING; CELL CYCLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; GENE OVEREXPRESSION; MOUSE; MUTATION; MYELOID LEUKEMIA; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION;

ANIMALIA;

EID: 27744440147     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Zirwes RF, Schmidt-Zachmann MS, Franke WW. Identification of a small, very acidic constitutive nucleolar protein (NO29) as a member of the nuclophosmin family. Proc Natl Acad Sci USA 1997; 94:11387-92.
2. Dundr M, Olson MO. Partially processed pre-rRNA is preserved in association with processing components in nucleolus-derived foci during mitosis. Mol Biol Cell 1998; 9:2407-22.
3. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000; 275:24451-7.
4. Huang N, Negi S, Szebani A, Olson MO. Protein NPM3 interacts with the multifunctional nucleolar protein B23/nucleophosmin and inhibits ribosome biogenesis. J Biol Chem 2005; 280:5496-502.
5. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan P-K, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, Fukasawa K. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103:127-40.
6. Tokuyama Y, Horn HF, Kawamura K, Tarapore P, Fukasawa K. Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J Biol Chem 2001; 276:21529-37.
7. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, Pandolfi PP. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437:147-53.
8. Piazza F, Gurrieri C, Pandolfi PP. The theory of APL. Oncogene 2001; 20:7216-22.
9. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001; 20:5623-37.
10. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo Coco F, Pelicci PG, Martelli MF. Cyto-plasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New Eng J Med 2005; 352:254-66.
11. Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, Locatelli F, Martelli MF, Basso G, Pession A, Biondi A, Falini B. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005; 106:1419-22.
12. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosomal biogenesis and cell proliferation. Mol Cell 2003; 12:1151-64.
13. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004; 24:985-96.
14. Kuo M-L, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes & Devel 2004; 18:1862-74.
15. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003; 13:77-83.
16. Llanos S, Clark PA, Rowe J, Peters G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 2001; 3:445-52.
17. Korgaonkar C, Hagan J, Tompkins V, Frazier AA, Allamargot C, Quelle FW, Quelle DE. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005; 25:1258-71.
18. Carnero A, Hudson JD, Price CM, Beach DH. p16INK4a and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2000; 2:148-55.
19. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19ARF tumor suppressor. Genes Dev 2000; 14:2358-65.
20. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-independent repression of NF-KB transactivation by the ARF tumor suppressor. Mol Cell 2003; 12:15-25.
21. Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR. p19ARF directly and differen-tially controls the functions of c-Myc independently of p53. Nature 2004; 431:712-7.
22. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, Raychaudhuri P. Myc-ARF (alternative reading frame) interaction inhibits the functions of Myc. J Biol Chem 2004; 279:36698-707.
23. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003; 11:415-24.
24. Xirodimas DP, Chisholm J, Desterro JMS, Lane DP, Hay RT. p14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 2002; 528:207-11.
25. Woods YL, Xirodimas DP, Prescott AR, Sparks A, Lane DP, Saville MK. p14ARF promotes small ubiquitin-like modifier conjugation of Werners helicase. J Biol Chem 2004; 279:50157-66.
26. Rizos H, Woodruff S, Kefford RF. p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle 2005; 4:597-603.
27. Tago, K., Chiocca, S., and Sherr, C. J. Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc Nat Acad Sci USA 2005; 102:7689-7694.
28. Kuo M-L, Duncavage EJ, Mathew R, den Besten W, Pie D, Naeve D, Yamamoto T, Cheng C, Sherr CJ, Roussel MF. Arf induces p53-dependent and independent anti-proliferative genes. Cancer Res 2003; 63:1046-53.
29. Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl AJ, Sherr CJ, McKinnon P. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled Atm function. Cancer Res 1999; 59:2464-9.
30. Hanawa H, Persons DA, Nienhuis AW. High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells. Hum Gene Ther 2002; 13:2007-16.
31. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Nat Acad Sci USA 1996; 93:11400-6.
32. Bertwistle D, Zindy F, Sherr CJ, Roussel MF. Monoclonal antibodies to the mouse p19Arf tumor suppressor protein. Hybridoma and Hybridomics 2005; 23:293-300.
33. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12:2424-33.
34. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.
35. Nakagawa M, Kameoka Y, Suzuki R. Nucleophosmin in acute myelogenous leukemia. New Eng J Med 2005; 352:1819-20.
36. Okuwaki M, Tsujimoto M, Nagata K. The RNA binding activity of ribosome biogenesis factor, nucleophosmin/B23, is modulated by phosphorylation with a cell cycle-dependent kinase and by association with its subtype. Mol Biol Cell 2002; 13:2016-30.
37. Grisendi S, Pandolfi PP. NPM mutations in acute myelogenous leukemia. New Eng J Med 2005; 352:291-2.
38. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 103:379-90.
39. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005; 7:823-30.
40. Westphal CH, Schmaltz C, Rowan S, Elson A., Fisher DE, Leder P. Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res 1997; 57:1664-67.
41. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
42. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
43. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121:1071-83.